Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q2 2023 · 10-Q
Revenue$19.79M$19.79M+418.0% vs Q2 2022 Net Income-$11.89M-$11.89MN/M vs Q2 2022 EPS Diluted-$3.13-$3.13N/M vs Q2 2022 Operating Income-$3,129,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$22,210,000N/M Margins · derivedOperating margin-15.8%+757.9 pt vs Q2 2022
Net margin-60.1%+752.3 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 4, 2023 · 35 d after period end